Therapeutic Options in IgG4-Related Disease
Sign Up to like & getrecommendations! Published in 2020 at "Current Treatment Options in Rheumatology"
DOI: 10.1007/s40674-020-00147-w
Abstract: Purpose of review IgG4-related disease (IgG4-RD) is an autoimmune fibrosing condition which is being increasingly recognized. This condition has been classically managed with glucocorticoids (GC) with variable dosing and frequent relapses. Multiple observational reports studied… read more here.
Keywords: related disease; steroid sparing; treatment; sparing agents ... See more keywords
Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis
Sign Up to like & getrecommendations! Published in 2019 at "Neuromuscular Disorders"
DOI: 10.1016/j.nmd.2019.06.002
Abstract: Rituximab is a chimeric monoclonal antibody that binds CD20 and causes the depletion of B-cell subsets. Although initially designed to treat lymphoma, it has found wide use in the management of various autoimmune conditions, including… read more here.
Keywords: agents initiation; stopping oral; steroid sparing; oral steroid ... See more keywords
Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease
Sign Up to like & getrecommendations! Published in 2018 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-017-0081-5
Abstract: Inhibition of the Janus-associated kinases (JAK) with ruxolitinib (RUX) reduces graft-versus-host disease (GVHD) in preclinical and clinical models. In total 19 allograft recipients with moderate/severe steroid-dependent chronic GVHD received RUX as ≥2nd line salvage. RUX… read more here.
Keywords: steroid sparing; sparing agent; versus host; agent chronic ... See more keywords
The Steroid-Sparing Effect of Adalimumab in the Treatment for the Recurrent Phase of Vogt–Koyanagi–Harada Disease
Sign Up to like & getrecommendations! Published in 2022 at "Ocular Immunology and Inflammation"
DOI: 10.1080/09273948.2022.2037657
Abstract: ABSTRACT Purpose To reveal the steroid-sparing effect of adalimumab (ADA) in the treatment for the chronic recurrent phase of Vogt–Koyanagi–Harada (VKH) disease. Cases and methods Thirty-six eyes from 18 cases of the recurrent phase of… read more here.
Keywords: disease; recurrent phase; sparing effect; steroid sparing ... See more keywords
Steroid-sparing effect of anakinra in giant-cell arteritis: a case series with clinical, biological and iconographic long-term assessments.
Sign Up to like & getrecommendations! Published in 2021 at "Rheumatology"
DOI: 10.1093/rheumatology/keab280
Abstract: OBJECTIVES The treatment of giant cell arteritis (GCA) relies on corticosteroids but is burdened by a high rate of relapses and adverse effects. Anti-interleukin-6 treatments show a clear benefit with a significant steroid-sparing effect, but… read more here.
Keywords: giant cell; sparing effect; steroid sparing; cell arteritis ... See more keywords
Efficacy of leflunomide as a steroid-sparing agent in treatment of Indian giant cell arteritis patients: A 2-year follow-up study.
Sign Up to like & getrecommendations! Published in 2022 at "International journal of rheumatic diseases"
DOI: 10.1111/1756-185x.14319
Abstract: OBJECTIVES To evaluate the effectiveness of leflunomide as a steroid-sparing agent among Indian patients with giant cell arteritis (GCA) and to assess the changes of "halo sign" within affected arteries, detected ultrasonographically, after remission. METHODS… read more here.
Keywords: sparing agent; giant cell; steroid sparing; study ... See more keywords
Successful use of apremilast as a steroid‐sparing agent in chronic actinic dermatitis
Sign Up to like & getrecommendations! Published in 2020 at "Dermatologic Therapy"
DOI: 10.1111/dth.13809
Abstract: Dear Editor, Chronic actinic dermatitis (CAD) is an immune-mediated photosensitive skin disease, characterized by persistent eczematous skin lesions, predominantly affecting sun-exposed areas. Severe, refractory disease entails use of systemic immunosuppressants like corticosteroids. Apremilast is a… read more here.
Keywords: actinic dermatitis; apremilast; chronic actinic; successful use ... See more keywords
Evaluating the Incidence and Risk Factors for Acute Cellular Rejection in a Steroid Sparing Liver Transplant Center
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Pharmacotherapy"
DOI: 10.1177/10600280221120059
Abstract: Background: Corticosteroids has been the mainstay of immunosuppression (IMS) following liver transplant (LT). With the advent of more potent IMS, complete steroid withdrawal has become possible after LT. However, there is limited data regarding the… read more here.
Keywords: liver transplant; incidence; center; risk factors ... See more keywords
Maintained disease control and steroid-sparing effect of subcutaneous immunotherapy in allergic rhinitis and asthma.
Sign Up to like & getrecommendations! Published in 2022 at "Asian Pacific journal of allergy and immunology"
DOI: 10.12932/ap-030921-1222
Abstract: BACKGROUND Allergen immunotherapy is the only currently available treatment strategy that modifies the immune response to the causative allergen and induces clinical improvement and a steroid-sparing effect. OBJECTIVE In this real-life study, we aimed to… read more here.
Keywords: rhinitis; control; allergic rhinitis; steroid sparing ... See more keywords
A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.839075
Abstract: Background and Purpose Two clinical trials assessing the steroid-sparing effect of methotrexate (MTX) yielded conflicting results. Our objective was to investigate whether MTX would show a steroid-sparing effect in the treatment of generalized myasthenia gravis… read more here.
Keywords: prednisone; mtx; class; steroid sparing ... See more keywords
Performance of leflunomide as a steroid-sparing agent in giant cell arteritis: A single-center, open-label study
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2022.1069013
Abstract: Background The management of giant cell arteritis (GCA) remains challenging and many patients require prolonged glucocorticoid treatment due to high disease relapse rates. We aimed to evaluate the role of leflunomide as a steroid-sparing agent… read more here.
Keywords: leflunomide steroid; leflunomide; giant cell; group ... See more keywords